Nanoliposomal PD-1 antagonist target tumor-draining lymph nodes to revitalize T cells and improve anti-tumor effect in hepatocellular carcinoma
{{output}}
Background: Tumor-draining lymph nodes (TdLNs) are pivotal in tumor immunotherapy, including the action of immune checkpoint inhibitors such as PD-1/PD-L1 blockade. However, fully harnessing the therapeutic potential of TdLNs to ... ...
